Danyal Khan

Danyal Khan

Auto-generated profile, based on publicly available information

Danyal Khan

Department of Pediatric Cardiology, Niklaus Children’s Hospital, Miami, FL (D.M.K.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
TJThomas K. Jones
Thomas K. Jones
DMDoff B. McElhinney
Doff B. McElhinney
JVJulie A. Vincent
Julie A. Vincent
WHWilliam E. Hellenbrand
William E. Hellenbrand
JCJohn P. Cheatham
John P. Cheatham
LBLisa J. Bergersen
Lisa J. Bergersen
Background: The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reducing the lifetime burden of surgery for patients with complex congenital heart disease. Methods: Enrollment for the US Investigational Device Exemption study of the Melody valve began in 2007. Extended follow-up was completed in 2020. The primary outcome was freedom from transcatheter pulmonary valve (TPV) dysfunction (freedom from reoperation, reintervention, moderate or severe pulmonary regurgitation, and/or mean RVOT gradient >40 mm Hg). Secondary end points included stent fracture, catheter reintervention, surgical conduit replacement, and death. Results: One hundred seventy-one subjects with RVOT conduit or bioprosthetic pulmonary valve dysfunction were enrolled. One hundred fifty underwent Melody TPV replacement. Median age was 19 years (Q1–Q3: 15–26). Median discharge mean RVOT Doppler gradient was 17 mm Hg (Q1–Q3: 12–22). The 149 patients implanted >24 hours were followed for a median of 8.4 years (Q1–Q3: 5.4–10.1). At 10 years, estimated freedom from mortality was 90%, from reoperation 79%, and from any reintervention 60%. Ten-year freedom from TPV dysfunction was 53% and was significantly shorter in children than in adults. Estimated freedom from TPV-related endocarditis was 81% at 10 years (95% CI, 69%–89%), with an annualized rate of 2.0% per patient-year. Conclusions: Ten-year outcomes from the Melody Investigational Device Exemption trial affirm the benefits of Melody TPV replacement in the lifetime management of patients with RVOT conduits and bioprosthetic pulmonary valves by providing sustained symptomatic and hemodynamic improvement in the majority of patients. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00740870.

1 November 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
Bibhuti B DasBibhuti B Das
Bibhuti B Das
UKUtkarsh Kohli
Utkarsh Kohli
PRPreeti Ramachandran
Preeti Ramachandran
HNHoang H. Nguyen
Hoang H. Nguyen
GGGerald Greil
Gerald Greil
DKDanyal Khan
Danyal Khan

1 January 2020 in IDCases
Verified
Journal Article
Open access
TWTaylor Wang
Taylor Wang
DKDanyal Khan
Danyal Khan
NMNeville Mobarakai
Neville Mobarakai
Erysipelothrix rhusiopathiae is a zoonotic gram positive coccobacillus. It is rarely found in humans as an occupational pathogen that mainly infects animal handlers. There are three forms of human infection: localized erysipeloid, diffuse cutaneous form and lastly, bacteremia that could progress to infective endocarditis. We present a case of a 59-year-old male who was found to have E. rhusiopathiae bacteremia that was diagnosed as aortic valve endocarditis with severe aortic regurgitation. The patient was treated with ampicillin-sulbactam then transitioned to six weeks of intravenous ampicillin. This report summarizes a rare organism that causes a serious human infection and discusses its epidemiology, clinical presentation, diagnosis and treatment options.

22 December 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
UKUtkarsh Kohli
Utkarsh Kohli
LDLavina Desai
Lavina Desai
DCDevyani Chowdhury
Devyani Chowdhury
AHAshraf S. Harahsheh
Ashraf S. Harahsheh
AYAlexandra B. Yonts
Alexandra B. Yonts
JAJocelyn Y. Ang
Jocelyn Y. Ang

18 March 2021 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
MRMegan L. Ringle
Megan L. Ringle
Rohit LoombaRohit Loomba
Rohit Loomba
JDJohn C. Dykes
John C. Dykes
DKDanyal Khan
Danyal Khan
DSDavid Schidlow
David Schidlow
GWGil Wernovsky
Gil Wernovsky
Isomerism, also referred to as “heterotaxy” is a complex set of anatomic and functional perturbations. One of the most obvious manifestations of isomerism is the disturbance of organ arrangement, such that the thoracic organs are no longer asymmetric on the left and right. We report the case of a 14-year-old female in whom exercise-induced dyspnea led to a late diagnosis of left isomerism complicated by Abernethy malformation and portopulmonary hypertension. A comprehensive evaluation revealed two anatomic left lungs and hyparterial bronchi, bilateral left atria, an interrupted inferior caval vein with azygos continuation, multiple spleens, sinus node dysfunction, hepatic hypertrophy with focal nodular hyperplasia, and absence of the portal vein. Pulmonary vasodilator therapy was initiated resulting in clinical improvement. This case exhibits unique features including a late diagnosis of isomerism with Abernethy malformation and portopulmonary hypertension. The patient’s presentation, medical workup, and future treatment emphasise the importance of multidisciplinary care in children with complex multisystem disease. We review the multiple cardiac and extracardiac manifestations of isomerism.